Ross Camidge, MD, PhD, University of Colorado Aurora, Colorado, USA, discusses updates in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and his thoughts on interpreting the data from clinical trials to better treat patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).